First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis

BackgroundThe benefit of first-line use of sodium-dependent glucose transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes mellitus (T2DM) with low risk of cardiovascular diseases are not clear.MethodsPubMed, EMBASE and Cochrane Library databases...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Rui Deng, Kaibo Mei, Tiangang Song, Jinyi Huang, Yifan Wu, Peng Yu, Zhiwei Yan, Xiao Liu
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2024-01-01
סדרה:	Frontiers in Endocrinology
נושאים:	sodium-glucose cotransporter 2 inhibitors glucagon-like peptide-1 receptor agonists type 2 diabetes metformin meta-analysis
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1289643/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!